| |
All patients (N = 185)
|
|---|
|
Age (years)
|
70 (61–78)
|
|
Male, n (%)
|
130 (70.2)
|
|
Hypertension, n (%)
|
148 (80.0)
|
|
Diabetes mellitus, n (%)
|
100 (54.1)
|
|
Dyslipidemia, n (%)
|
80 (43.2)
|
|
Ischemic heart disease, n (%)
|
74 (40.0)
|
|
Stroke, n (%)
|
27 (14.9)
|
|
ABI
|
1.18 (1.05–1.27)
|
|
SPP (mmHg)
|
73 (52–85)
|
|
Previous history of PAD, n (%)
|
13 (7.0)
|
|
Medications
|
|
Cilostazol, n (%)
|
11 (5.9)
|
|
Sarpogrelate, n (%)
|
1 (0.5)
|
|
Aspirin, n (%)
|
48 (25.9)
|
|
Prostaglandin analogue, n (%)
|
17 (9.2)
|
|
Ticlopidine, n (%)
|
18 (9.7)
|
|
Clopidogrel, n (%)
|
1 (0.5)
|
|
Warfarin, n (%)
|
6 (3.2)
|
|
Dipyridamole, n (%)
|
10 (4.9)
|
|
Dilazep, n (%)
|
9 (5.4)
|
|
ARB, n (%)
|
74 (40.0)
|
|
Statin, n (%)
|
60 (32.4)
|
- Data are presented as median (interquartile range)
- ABI ankle brachial pressure index, SPP skin perfusion pressure, PAD peripheral arterial disease, ARB angiotensinII receptor blocker
